# Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

> **NCT06462014** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 507 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Relugolix

## Key facts

- **NCT ID:** NCT06462014
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-19
- **Primary completion:** 2024-12-13
- **Final completion:** 2024-12-13
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462014, "Description of Relugolix Use in Patients With Prostate Cancer Within the VHA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06462014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*